Relmada Therapeutics’ Lawsuit against Laidlaw & Company

Laidlaw & Company is a U.K. based investment banking firm that offers brokerage advice and personalized banking services to private and public institutions as well as high-net-worth investors. The company became a member of York State Exchange in 1878. Laidlaw & Company’s top executives are Mathew D. Eitner who serves as the CEO while James P. Ahern is the Head of Capital Markets.

Laidlaw & Company is a leading provider of wealth management and investment banking services in the US and the UK. The firm helps clients to raise capital through equity placement in the securities trade markets and initial public offerings.

Laidlaw & Company breaches a confidential contract

In Dec 2015, Relmada Therapeutics filed a lawsuit against Laidlaw & Company and its executives Mathew Eitner and James Ahern.  Besides, they issued a false and misleading information in an attempt to take total control over Relmada Therapeutics. As such, Relmada Therapeutics amended its previous lawsuit against Laidlaw & Company’s officials to include claims of breaching a confidential agreement while the company served as its investment banker. Relmada Therapeutics seeks monetary compensation citing financial loss and reputation damages due to the dissemination of misleading proxy materials. Relmada Therapeutics noted that its stock price declined from $4.03 to $1.65 per share after Laidlaw & Company breached a confidential agreement.

While he claims to have graduated from Assumption College in 2002, college records confirm that he attended school from 1999 to 2000. Interestingly, there is no data to support the claim that he graduated college in 2002. Furthermore, statistics reveal over three customer complaints and two lawsuits filed against James Ahern between 2011 and 2012. Under the leadership of Mathew Eitner and James Ahern, Laidlaw & Company received several customer complaints about poor customer service.